Physician profile
Dao Tran
NPI 1659771368
$866.02
in general payments reported to CMS, 2019-2025
13 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $46.74 · 2022: $19.83 · 2023: $32.35 · 2024: $278 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $221.32 | 2024-2025 | Dovato |
| Scilex Pharmaceuticals INC. | $214.78 | 2024-2025 | |
| Dexcom, INC. | $114.00 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $62.67 | 2019-2020 | |
| Gilead Sciences, INC. | $49.05 | 2019-2025 | |
| Amarin Pharma, INC. | $45.80 | 2019-2020 | |
| Sanofi Pasteur INC. | $33.24 | 2019-2022 | |
| Abbott Laboratories | $32.29 | 2023-2024 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $26.13 | 2025 | Aptima |
| Astellas Pharma US INC | $21.89 | 2024 | Veozah |
| Alkermes, INC. | $17.45 | 2019 | |
| Phadia US INC. | $13.94 | 2019 | |
| Novo Nordisk INC | $13.46 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dao Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.